Pura Vida Investments’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Pura Vida Investments’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-206,525	Closed	-$1.21M	–	199
2022 Q4	$1.21M	Buy	+206,525	New	+$1.09M	0.06%	142
2022 Q3	–	Sell	-44,357	Closed	-$187K	–	272
2022 Q2	$187K	Buy	+44,357	New	+$176K	0.01%	191
2021 Q1	–	Sell	-293,443	Closed	-$3.71M	–	277
2020 Q4	$3.71M	Buy	+293,443	New	+$3.34M	0.13%	117

Pura Vida Investments's CNCE Position: Q1 2023 in Review

Pura Vida Investments sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 206,525 shares — an estimated $1.21M sold.

Pura Vida Investments first reported a position in CNCE in Q4 2020 and held it in 3 quarters. The position peaked at $3.71M in Q4 2020. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

Pura Vida Investments reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Pura Vida Investments sold 206,525 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $1.21M.
Pura Vida Investments first reported a position in Concert Pharmaceuticals, Inc. in Q4 2020 and held it in 3 quarters.
Pura Vida Investments's Concert Pharmaceuticals, Inc. position peaked at $3.71M in Q4 2020.
0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.